PDUFA V focus on speedy approval of new drugs by US FDA is misguided, suggests study
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration faces constant criticism from the pharmaceutical industry for being too slow with drug approvals but a new study shows that the FDA has in fact been faster than its counterparts in the EU and Canada at approving novel therapeutics over the last decade1.